​Key Markets We Serve

  • Experts in over 50 therapeutic categories

  • Global presence - we support clients in a variety of Asian and European markets

  • Full range of client types, including venture backed start-ups

Common Mistakes When Entering the US Market

Under-Valuing the Payer Landscape

US health insurers have a high-level of control over the access to pharmaceuticals. With over 1,000 health insurance companies and numerous benefit designs, it is critical to target the right entities, leveraging key relationships.

Inadequate Value Platform

Influence over health insurers, physicians, and patients will require customized tailored messaging that addresses the unique concerns of each. The right trade-off between clinical and cost, as well as overall system savings is key to US market success.

Inaccurate Competitive


US market strategy is based on the current and upcoming competitive landscape. Inadequate or inaccurate intelligence can negatively impact market entry or worse, advantage competitors.

US  Commercialization Services

Independent Market Entry

  • Cost-Effective Manufacturing Establish Product Value Platform

  • Marketing & Sales

  • Distribution

  • Market Access

  • Contracting & Pricing

  • FDA, Regulatory & Compliance Access to Payers

Co-Promotion & Marketing Partnership

  • Qualify Viable Partners

  • Market Research

  • Evaluation of Product Potential in US Market

  • Leverage Network

  • Facilitate & Coordinate Discussions Negotiate Terms

  • Close the Deal

Acquire &

Divest Assets

  • In-Licensing & Out-Licensing

  • Gross-to-Net Determinations

  • Acquisitions / Divestment

  • M&A Support

  • Portfolio Realignment

  • Strategies (spin-off, equity carve out, etc.)

  • Partner Due Diligence Review

Our Capabilities in Greater Detail

​D2 interacts and negotiates with key US market segments on a daily basis. We provided unparalleled connectivity and a deep understanding of how to optimize business development opportunities. We specialize in research, content, and deal development for a wide-range of life sciences entities.

  • D2 works for you, we are independent of state firms, financial institutions or manufacturers

  • Deep understanding and connectivity of the US market

  • Ability to determine the “Gross to Net” potential of a molecules to develop the right deal models

  • D2 provides intelligence so international clients are not “tricked” or loose on licensing of products

  • We provide accurate information on how the products will be paid for by payers in the US market

  • D2 provides ongoing support, acting as a conduit on behalf of our international partners to provide ongoing visibility into challenges and success of their products in the US marketplace